Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age above 18years 2.Performance status 0-1 3.Hisologically confirmed invasive colorectal adeno carcinoma 4.Measuramble metastatic disease/M1/STAGE 4colorectal cabncer 5. Patient willing to give informed consent. 6.
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with stage 1-3 colorectal cancer 2.Poor performance status 3.Patient not willing or not planned for definitive management of colorectal cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rudimentary data on utility of CTC and CtDNA in treatment monitoring in metastatic colorectal cancers.Timepoint: Collection of blood samples at 0 weeks of planned treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. CTC levels in comparison with conventional response assessment methods like Serum CEA & cross sectional imaging. 2. To explore simple, cost effective solutions in personalized medicine.Timepoint: Collection of blood samples at 6,12 weeks of planned treatment | — |
Countries
India
Contacts
Aster CMI Hospital